J Cancer 2020; 11(7):1751-1760. doi:10.7150/jca.37958 This issue
1. Graduate School, Guangzhou Medical University, Guangzhou 510182, China
2. Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen 518036, China
3. Department of Oncology, Peking University Shenzhen Hospital, Shenzhen 518036, China
4. Anhui Medical University, Hefei 230000, Anhui Province, China
*These authors contributed equally to this work.
Background: Bladder cancer (BC) is one of the most common malignancies world-wide with high morbidity and mortality. Long noncoding RNAs (lncRNAs) are thought to play a critical role in cancer development. LncRNA NRON, a repressor of activated T-cell nuclear factor (NFAT), has been shown to be dysregulated in many cancer types. However, the clinical significance and molecular mechanism of NRON in bladder cancer is still unknown.
Methods: The expression levels of NRON in BC tissues and cell lines were tested by RT-qPCR. Survival analysis was performed to detect the correlation between NRON expression and clinical outcomes in patients with BC. The biological role of NRON in BC cells proliferation and metastasis was examined in vitro and in vivo.
Results: The expression of NRON was significantly upregulated in BC specimens and cell lines compared with paired adjacent normal tissues and normal cell lines. The upregulation of NRON in bladder cancer patients was significantly associated with the depth of bladder tumor invasion and poor prognosis. Knockdown of NRON inhibited BC cells proliferation, migration, invasion and tumorigenicity. Furthermore, NRON promoted epithelial-mesenchymal transition (EMT) progression, and NRON-induced EZH2 expression contributed to this process.
Conclusion: In conclusion, our results suggested that NRON acted as an oncogene and tumor biomarker for BC.
Keywords: long non-coding RNA, lncRNA NRON, bladder cancer, oncogene, EMT